Moore Matthew Richard 4
4 · Arcutis Biotherapeutics, Inc. · Filed Sep 12, 2023
Insider Transaction Report
Form 4
Moore Matthew Richard
SVP and Chief Business Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-08-29+12,500→ 12,500 totalExercise: $28.72Exp: 2031-01-18→ Common Stock (12,500 underlying)
Footnotes (1)
- [F1]1/48th of the shares vest on each monthly anniversary of the milestone vesting commencement date, beginning on September 29, 2023, subject to the Reporting Person's provision of service to the Issuer on each vesting date.